| Mrs Lesa Orlando Lewandowski, PAC | |
|
170 Medical Park Rd, Suite103, Mooresville, NC 28117-8540 | |
| (704) 660-4094 | |
| (704) 660-8901 |
| Full Name | Mrs Lesa Orlando Lewandowski |
|---|---|
| Gender | Female |
| Speciality | Physician Assistant |
| Experience | 32 Years |
| Location | 170 Medical Park Rd, Mooresville, North Carolina |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306801998 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | 103206 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lake Norman Regional Medical Center | Mooresville, NC | Hospital |
| Novant Health Huntersville Medical Center | Huntersville, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lake Norman Pulmonary And Sleep, Pa | 5092798314 | 3 |
News Archive
New UBC research has found that amplified electroencephalograms (EEGs) can produce diagnostic results of a brainwave associated with migraines and epilepsy that are comparable to the current, more invasive, standard-a discovery that could lead to better treatment and diagnosis of these conditions.
Ear infections are one of the most common health problems for children, with most kids experiencing at least one by their third birthday. Annual costs in the United States alone are in the billions of dollars.
MAP Pharmaceuticals, Inc. announced today that it will present analysis of data from the efficacy portion of the first Phase 3 trial of its novel LEVADEX orally inhaled migraine therapy, currently in development, at the 14th Congress of the International Headache Society.
Researchers at the University of Michigan Comprehensive Cancer Center have identified a new imaging technique that can measure the effectiveness of treatment for prostate cancer that has spread to the bones.
Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), today announced positive top-line results from a pivotal, non-human primate study of its novel, once-a-day, oral antibiotic Restanza(TM) (cethromycin) against an inhaled lethal dose of tularemia. A 14-day course of Restanza achieved a 100% survival rate at the doses tested. All of the ten animals in the study that received 16 mg/kg once-a-day of Restanza (approximate to a human dose of 300 mg) within 24 hours after exposure to a lethal dose of inhaled tularemia survived while only one of the ten animals that received placebo survived.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Lesa Orlando Lewandowski, PAC 170 Medical Park Rd, 103, Mooresville, NC 28117-8540 Ph: (704) 660-4094 | Mrs Lesa Orlando Lewandowski, PAC 170 Medical Park Rd, Suite103, Mooresville, NC 28117-8540 Ph: (704) 660-4094 |
News Archive
New UBC research has found that amplified electroencephalograms (EEGs) can produce diagnostic results of a brainwave associated with migraines and epilepsy that are comparable to the current, more invasive, standard-a discovery that could lead to better treatment and diagnosis of these conditions.
Ear infections are one of the most common health problems for children, with most kids experiencing at least one by their third birthday. Annual costs in the United States alone are in the billions of dollars.
MAP Pharmaceuticals, Inc. announced today that it will present analysis of data from the efficacy portion of the first Phase 3 trial of its novel LEVADEX orally inhaled migraine therapy, currently in development, at the 14th Congress of the International Headache Society.
Researchers at the University of Michigan Comprehensive Cancer Center have identified a new imaging technique that can measure the effectiveness of treatment for prostate cancer that has spread to the bones.
Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), today announced positive top-line results from a pivotal, non-human primate study of its novel, once-a-day, oral antibiotic Restanza(TM) (cethromycin) against an inhaled lethal dose of tularemia. A 14-day course of Restanza achieved a 100% survival rate at the doses tested. All of the ten animals in the study that received 16 mg/kg once-a-day of Restanza (approximate to a human dose of 300 mg) within 24 hours after exposure to a lethal dose of inhaled tularemia survived while only one of the ten animals that received placebo survived.
› Verified 8 days ago
Aileen Deng, Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 170 Medical Park Rd Ste 101, Mooresville, NC 28117 Phone: 980-302-7070 Fax: 980-302-7075 | |
Laila Noor Menon, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 170 Medical Park Rd, Mooresville, NC 28117 Phone: 704-664-9506 | |
Patrick L. Fry, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 170 Medical Park Rd, Ste 140a, Mooresville, NC 28117 Phone: 704-663-4443 | |
Dr. Suraj Arora, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 134 Medical Park Rd Ste 200, Mooresville, NC 28117 Phone: 704-384-7972 Fax: 704-384-7973 | |
Richard Krumdieck, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 170 Medical Park Road, Ste 101, Mooresville, NC 28117 Phone: 704-799-3946 Fax: 704-799-3956 | |
Dr. Stephen Peter Stowe, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 603 East Center St, Suite A, Mooresville, NC 28115 Phone: 704-663-5090 Fax: 704-663-5502 | |
Dr. Smitha Reddy Pasula, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 930 W Wilson Ave, Mooresville, NC 28117 Phone: 704-663-7500 |